News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Phase II
Innapharma: Completion Of Target Enrollment In The Phase 2 EffiKIR Trial 7/24/2014
Celsion Corporation (CLSN) Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study In Breast Cancer 7/24/2014
Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014
Biotron Limited (BIT:AU) BIT225 Reverses HIV-Induced Impairment Of The Immune System 7/23/2014
Inovio Pharmaceuticals (INO) HPV Immunotherapy Achieves Primary Efficacy Endpoint In Randomized Phase 2 Cervical Dysplasia Trial 7/23/2014
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/23/2014
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China 7/21/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014
Anavex Life Sciences Corp. (AVXL.OB) Achieves Key Milestone As It Secures Cgmp Manufacturing For Drug Candidate Trial Supplies 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a) 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
Synergy Pharmaceuticals Completes Patient Enrollment For Its SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Targacept, Inc. (TRGT) Stops Alzheimer's Drug Trial After It Fails Phase 2b Trial 7/16/2014
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014
Adynxx Initiates Phase 2 Dose-Ranging Study Of AYX1, Lead Compound For The Prevention Of Post-Surgical Pain 7/16/2014
Resolve Therapeutics Initiates Phase 2 Clinical Study In SLE 7/16/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
GenSpera Presents G-202 HCC Clinical Trial Update At 5th Asia-Pacific Primary Liver Cancer Expert Meeting 7/15/2014
Amarantus BioSciences, Inc. Announces Positive Clinical Performance And 7-Year Longitudinal Data Poster Presentations For Lympro Test® At AAIC 2014 7/15/2014
CellAct Pharma Receives Orphan Drug Designation In EU For CAP7.1 In Biliary Tract Cancers 7/15/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014
Genticel’s Phase 2 Study With ProCervix Passes The Halfway Mark For Patient Recruitment 7/10/2014
Latest Sarepta Therapeutics (SRPT) Phase 2 Data Shows Greater Decline in Walking Ability For Muscular Dystrophy Patients 7/10/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Tames Eczema In Phase 2b Trial 7/10/2014
Cytokinetics, Inc. (CYTK) Announced Additional Results Relating To Tirasemtiv From Pre-Specificed Subgroup Analyses Of BENEFIT-ALS 7/10/2014
Zafgen (ZFGN) Granted Orphan Drug Designation In The European Union For Beloranib, A First-In-Class Metap2 Inhibitor For The Treatment Of Prader-Willi Syndrome 7/10/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
Boehringer Ingelheim Corporation's Breakthrough Cancer Drug Volasertib Effective In Phase 2 Trial 7/9/2014
National Institutes of Health (NIH) Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS Systemnational 7/9/2014
Acasti Pharma Completes Phase 2 Double Blind (TRIFECTA) And Pharmacokinetic Trials 7/9/2014
Adocia Announces Approval To Start A Phase IIa Clinical Study Of Hinsbet®, Its Fast-Acting Human Insulin, In Type 1 Diabetes 7/9/2014
Lexicon Pharmaceuticals, Inc. (LXRX) And Juvenile Diabetes Research Foundation Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes 7/9/2014
480 Biomedical Awarded $1 Million Phase II NHLBI Contract To Advance Bioresorbable Scaffold For Pediatric Pulmonary Artery Stenosis 7/9/2014
Opko Health, Inc.'s Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations In Europe 7/9/2014
NeoStem, Inc. Presents Five-Year Survival Data For Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells At American Society of Clinical Oncology Annual Meeting 7/9/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
PRC Clinical Completes Over 800 Monitoring Visits In Global Phase 2b Neurology Study 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Avraham Pharmaceuticals Ltd. Announces Successful Interim Results In Phase 2b Study Of Ladostigil For The Treatment Of MCI 7/8/2014
CardioCell Begins Phase IIa Clinical Trial Using itMSC Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 7/8/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Patient Enrollment IN U.S. Randomized Phase 2 Pancreatic Cancer Study 7/8/2014
Synergy Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Plecanatide In Irritable Bowel Syndrome With Constipation 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Celladon Corporation Announces New Clinical Development Initiatives For MYDICAR® 7/7/2014
CASI Pharmaceuticals  (ENMD) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma 7/7/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
Amgen (AMGN) Wins FDA Breakthrough Therapy Designation For Investigational BiTE 7/3/2014
Quark Pharmaceuticals Inc. Announces Completion Of Phase 2 Trial Evaluating QPI-1002 For Prevention Of Delayed Graft Function In Kidney Transplant Patients 7/1/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of A Phase 2 Study Of KRN23 For Pediatric X-Linked Hypophosphatemia In The US And EU 7/1/2014
AVANIR Pharmaceuticals (AVNR) Announces Two Data Presentations Related To Pseudobulbar Affect (PBA) At The Alzheimer's Association International Conference (AAIC) 7/1/2014
Agenus (AGEN) Brain Cancer Vaccine Shows Extended Survival In Phase 2 Final Data Analysis 7/1/2014
Threshold Pharmaceuticals, Inc. (THLD) Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial Of TH-302 In Combination With Pemetrexed In Advanced Non-Squamous Non-Small Cell Lung Cancer 7/1/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment 7/1/2014
Molecular Partners AG Release: Stage 3 Phase 2 Study Of DARPin Abicipar Pegol (Previously MP0112) Supports Progressing To Phase 3 Development Program 7/1/2014
Agenus (AGEN)'s Brain Cancer Vaccine Doubles Survival Rate In Phase 2 Study 7/1/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
Mologen AG (MOLGF.PK): Cancer Immune Therapy MGN1703 Shows Outstanding Long-Term Responses 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Aclaris Therapeutics Announces Positive Results From Phase 2 Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Skin Tumor 6/30/2014
Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS 6/30/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Amunix, Inc. Congratulates Versartis, Inc. (VSAR) On Its Positive Phase 2a Results With VRS-317 6/30/2014
Burzynski Research Institute Announces Presentations At The 16th International Symposium On Pediatric Neuro-Oncology 6/27/2014
Bellerophon Therapeutics Completes Enrollment Of Its Phase 2 Trial Of Inopulse® For Treatment Of Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) 6/27/2014
Aerie Pharmaceuticals, Inc. (AERI) Soars As Combo Eye Drug Roclatan Performs Well In Phase 2b Trial; Stock Up +28.29% At Market Close (June 25, 2014) 6/26/2014
Coronado Biosciences (CNDO) Reports Topline Results From Investigator Initiated Pilot Study Of TSO In Adults With Autism Spectrum Disorder 6/26/2014
Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society 6/26/2014
Aurinia (ISA.TO) Initiates Phase 2b Clinical Trial Of Voclosporin To Treat Lupus Nephritis 6/26/2014
Nora Pharma Announces Initiation Of Phase 2 RESPONSE Research Study 6/26/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Agenus (AGEN) Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation 6/26/2014
Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury 6/26/2014
Massachusetts' Agenus (AGEN) Touts Positive Phase 2 Data From HerpV Study 6/26/2014
NeuralStem Inc.'s NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder 6/25/2014
GenSpera Releases 2014 Biotechnology Industry Organization (BIO) International Presentation And HCC Clinical Trial Update For G-202 6/25/2014
NovaBiotics Ltd Release: Initiation Of A Phase IIa Clinical Study For Lynovex® In Cystic Fibrosis 6/25/2014
Quark Pharmaceuticals Inc. Announces First Patient Dosed In A Phase 2a Trial Evaluating QPI-1007 For Neuroprotection In Patients With Acute Primary Angle Closure Glaucoma 6/25/2014
Antares Pharma, Inc. (ATRS) Release: Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector 6/25/2014
Synthetic Biologics, Inc. (SYN) Reports That Licensor Cedars-Sinai Medical Center Finds Eradication Of Gut Methane Improves Insulin Sensitivity And Lipid Profiles In Study Of Pre-Diabetic, Obese Patients 6/25/2014
Ohr Pharmaceutical (OHRP) To Host Conference Call And Webcast To Discuss Squalamine Interim Phase 2 Data In Wet-AMD 6/24/2014
Ohr Pharmaceutical (OHRP) Eye Drug Falls Short In Phase 2 Trial 6/24/2014
Versartis, Inc. (VSAR) Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results 6/24/2014
Karyopharm Therapeutics (KPTI) Initiates Registration-Directed, Randomized Study Of Selinexor (KPT-330) In Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) 6/24/2014
Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Actimab-A And Alpha-Particle Immunotherapy Platform Further Validated At Society For Nuclear Medicine Annual Meeting 6/24/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
XenoPort, Inc. (XNPT) Announces Initiation Of A Phase 2 Clinical Trial Of XP23829 In Patients With Psoriasis 6/23/2014
Genocea Biosciences Announces Positive Top-Line Phase 1 Results For Novel Universal Pneumococcus Vaccine Candidate GEN-004 6/23/2014
IP Group Plc – Portfolio Company Diurnal Reports Positive Phase 2 Results 6/23/2014
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014
Inovio Pharmaceuticals (INO) Initiates Cervical Cancer Clinical Trial 6/23/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce Regulatory Clearance For Initiating Phase Ii Study With Vpd-737 In Prurigo Nodularis 6/23/2014
Islet Sciences Highlights Remogliflozin Etabonate As Novel Treatment For Non-Alcoholic Steatohepatitis (NASH) 6/23/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
GenSpera (GNSZ) Releases Updated Corporate Video: "Genspera Has Targeted Its Active Ingredient Thapsigargin To Kill Only The Cells We Select: Cancer" 6/23/2014
Prima Biomed (PRR.AX)'s CAN-002 CVac™ Trial Published In Journal For ImmunoTherapy Of Cancer 6/23/2014
Madison Vaccines Announces Expansion Of A Phase 2 Clinical Trial For MVI-816, Its Lead DNA Vaccine For Prostate Cancer 6/23/2014
Opko Health, Inc. To Hold Conference Call To Discuss Six Month Data From Phase 2 hGH-CTP Trial 6/20/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Boehringer Ingelheim Corporation Initiates RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) In NVAF Patients Undergoing Ablation 6/20/2014
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014
Kadmon Corporation Initiates Phase 2a Portion Of KD020 Study In Autosomal Dominant Polycystic Kidney Disease 6/19/2014
GenSpera CEO, Craig Dionne, To Present Update On Lead Drug Candidate G-202 At 2014 Biotechnology Industry Organization (BIO) International Convention 6/19/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Asmacure Announces Top-Line Clinical Results For ASM-024 DPI In Ph 1/2a Trial 6/18/2014
MerLion Pharmaceuticals Pte Ltd Completes Recruitment In Finafloxacin Phase II cUTI Trial 6/18/2014
Flexion Therapeutics (FLXN) Announces Positive Topline Results From Phase 2a Pharmacokinetic Trial With Lead Compound FX006 6/18/2014
Recro Pharma (REPH) Announces Dosing Of First Patient In Phase 2b Clinical Trial Of Dex-IN For Treatment Of Acute Pain Following Surgery 6/17/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Galena Biopharma  (GALE) Completes Enrollment In GALE-301 Phase 2a Clinical Trial In Ovarian And Endometrial Cancers 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014
PsiOxus Therapeutics Limited Initiates "OCTAVE" Ovarian Cancer Study For Oncolytic Vaccine Enadenotucirev 6/17/2014
Mirati Therapeutics  (MRTX) Receives Orphan Drug Designation From U.S. FDA For Mocetinostat In Myelodysplastic Syndrome 6/17/2014
Bellerophon Therapeutics Completes Enrollment For Its Phase 2 Trial Of Inopulse® For Treatment Of Pulmonary Arterial Hypertension (PAH) 6/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Reports Final Phase 2 Data On ISIS-GCGR RX Showing Significant Reduction In Hba1c In Patients With Type 2 Diabetes 6/16/2014
Sanofi (France) (SAN.PA)'s Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added To Insulin Glargine 6/16/2014
Karyopharm Therapeutics (KPTI) Announces: FDA Considers The Effectiveness And Safety Technical Sections Complete To Support Conditional Approval For The New Animal Drug Application For Verdinexor (KPT-335) To Treat Lymphoma In Client Owned Dogs 6/16/2014
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014
ALK-Abello A/S’s Partner For Japan Announces Trial Results For House Dust Mite SLIT-Tablet 6/16/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In RUCAPANC Study 6/16/2014
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014
Cytokinetics, Inc. (CYTK) Announces Data Relating To Tirasemtiv Presented At The 2014 Annual Spinal Muscular Atrophy Conference 6/16/2014
Islet Sciences Presents Positive Clinical Results For Best-In-Class SGLT2 Inhibitor At American Diabetes Association Annual Meeting 6/16/2014
Novo Nordisk A/S (NVO) Release: New One-year Data of IDegLira Shows Glucose-Lowering Effect Was Maintained For People With Type 2 Diabetes 6/16/2014
Poxel’s Investigational Oral Agent - Imeglimin - Shows Unique Anti-diabetic Profile In Preclinical And Clinical Studies 6/16/2014
TG Therapeutics, Inc. (MHA)' TG-1101 (Ublituximab) In Combination With Ibrutinib Demonstrates Compelling Clinical Activity And Safety Profile In Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) And Mantle Cell Lymphoma (MCL) 6/13/2014
NOXXON Pharma AG Presents Updates On Phase II Studies With Olaptesed Pegol (NOX-A12) In CLL And MM And Lexaptepid Pegol (NOX H94) In Anemic Cancer Patients 6/13/2014
Amgen (AMGN)'s Psoriatic Arthritis Drug Brodalumab Maintains Efficacy After One Year Study 6/12/2014
Ruthigen Cleared To Initiate Human Clinical Trials For RUT58-60 In The U.S. 6/12/2014
Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 19th Congress Of The European Hematology Association 6/12/2014
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Initiates Randomized Phase 2 Trial Evaluating Tosedostat Plus Cytarabine For Older Patients With AML Or High-Risk MDS 6/12/2014
Umecrine Mood's Premenstrual Dysphoric Disorder (PMDD) Drug Fails Phase 2 Study 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
Receptos (RCPT) Surges As Lead Multiple Sclerosis Drug Meets Main Goal In Phase 2 Study; Stock Up +36.78% At Market Close (June 10, 2014) 6/11/2014
Isis Pharmaceuticals, Inc. (ISIS) To Host Investor Event To Discuss ISIS-GCGR Rx Phase 2 Data Presented At The 2014 American Diabetes Association Scientific Sessions 6/11/2014
Portola Pharmaceuticals, Inc. Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin 6/11/2014
Xenetic Biosciences Announces Dosing Of First Patient On Dialysis In Phase 2a Clinical Study Of Erepoxen® 6/11/2014
Inovio Pharmaceuticals (INO) Clarifies Facts Of Its VGX-3100 Phase 2 Trial And Immunotherapy Technology 6/11/2014
Quest PharmaTech Inc. Completes Patient Enrollment In Phase 2b Study Of Oregovomab For The Immunotherapy Of Ovarian Cancer 6/10/2014
Advaxis, Inc. Provides Business Update 6/10/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports High Response Rates In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 6/10/2014
Adamas Pharmaceuticals (ADMS) Announces Rater Training Data On ADS-5102 For Parkinson's Disease Patients With Levodopa-Induced Dyskinesia 6/10/2014
Caris Life Sciences Research Provides Key Clinical Insights On Immunotherapeutic Targets In A Broad Range Of Cancers 6/10/2014
iCo Therapeutics Inc. Announces Top-Line Primary Endpoint Data From iCo-007 Phase 2 Ideal Study In Diabetic Macular Edema 6/9/2014
Versartis, Inc. (VSAR) To Hold Conference Call To Discuss Six Month VRS-317 Phase 2a VERTICAL Clinical Trial Results 6/9/2014
Karyopharm Therapeutics (KPTI) Announces Initiation Of Phase 2 Study Of Selinexor (KPT-330) In Patients With Hormone Refractory Prostate Cancer (SHIP Study) 6/9/2014
FDA Grants Edison Pharmaceuticals, Inc.'s EPI-743 Orphan Status For Leigh Syndrome 6/9/2014
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans 6/9/2014
Breakthrough: AFFiRiS AG Claims A First In Alzheimer's Disease Therapy 6/6/2014
ImaginAb, Inc. Presents Initial Phase I/Iia Results For Prostate Imaging Agent At Society of Nuclear Medicine And Molecular Imaging (SNMMI) Annual Meeting 6/6/2014
Xeris Pharmaceuticals Announces Dosing Of First Patient In Phase 2 Clinical Trial Of Its Investigational Soluble Glucagon For The Treatment Of Mild-To-Moderate Hypoglycemia 6/6/2014
First Patient Enrolled In BrainStorm Cell Therapeutics Inc.'s Phase II ALS Trial At Massachusetts General Hospital 6/6/2014
Halozyme Therapeutics, Inc. (HALO) Soars After FDA Lifts Hold On Pancreatic Cancer Trial; Stock Up +12% At Market Close (June 5, 2014) 6/6/2014
Tolero Pharmaceuticals Presents Positive Interim Phase 2 Clinical Trial Results Of Alvocidib For The Treatment Of Front Line AML At 2014 American Society of Clinical Oncology Annual Meeting 6/5/2014
Clovis Oncology (CLVS) Shares Drop As Analysts Give Edge To Lung-Cancer Rival 6/5/2014
Vertex Pharmaceuticals (MA) (VRTX) Trial Suggests Kalydeco May Work In More Cystic Fibrosis Patients 6/5/2014
La Jolla Pharmaceutical Company (LJPC) Announces Completion Of Enrollment Of Phase 2 Extension Study Of GCS-100 In Chronic Kidney Disease 6/5/2014
Autifony Therapeutics Awarded £2.2 Million To Progress First-In-Class Drug For Tinnitus Into Phase 2a Study 6/4/2014
PsiOxus Therapeutics Limited Announces Positive Study Results Of Oncolytic Vaccine Enadenotucirev At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Incyte Corporation (INCY) Announces Full Results From Proof-Of-Concept Phase II RECAP Trial Of Jakafi® (Ruxolitinib) In Combination With Capecitabine In Patients With Metastatic Pancreatic Cancer 6/3/2014
ChemoCentryx, Inc. (CCXI)'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA 6/3/2014
Jazz Pharmaceuticals plc (JAZZ) Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 6/3/2014
Gilead Sciences, Inc. (GILD) Announces Updated Phase 2 Results For Investigational GS-9973 In Relapsed Chronic Lymphocytic Leukemia 6/3/2014
PV-10 Data Presented At The American Society of Clinical Oncology Annual Meeting Defines Path Forward For Provectus Biopharmaceuticals Inc. 6/3/2014
Novartis AG (NVS)'s Drug Zykadia™ Shrank Tumors In Phase 1 Study 6/3/2014
ChemoCentryx, Inc. (CCXI)'s Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements 6/2/2014
NewLink Genetics Dorgenmeltucel-L HyperAcute Immunotherapy For Melanoma Demonstrates Clinical Efficacy With Tumor Regression and Immune Activation 6/2/2014
Positive Interim Phase IIa ALS Data With BrainStorm Cell Therapeutics Inc.'s NurOwn Presented At Joint Congress Of European Neurology 6/2/2014
OncoSec Medical Inc. Presents Positive Phase 2 Interim Data Evaluating ImmunoPulse In Melanoma 6/2/2014
NewLink Genetics Presents Algenpantucel-L Clinical Data In Poster Discussion Session At American Society of Clinical Oncology 2014 Annual Meeting 6/2/2014
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014
Tokai Pharmaceuticals Presents New Clinical Data For Galeterone Among Patients With Advanced Prostate Cancer At American Society of Clinical Oncology 2014 6/2/2014
D-Pharm Ltd. Reports Completion Of The Second Dose Tier In Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 6/2/2014
Prima Biomed (PRR.AX) To Host Conference Call To Discuss Abstract Presented At American Society of Clinical Oncology On New Interim Overall Survival And Final Progression Free Survival Data For The Company's CAN-003 Trial 6/2/2014